A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
about
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.Lisdexamfetamine: A Review in Binge Eating Disorder.Psychopharmacological advances in eating disorders.
P2860
A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@ast
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@en
type
label
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@ast
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@en
prefLabel
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@ast
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@en
P2093
P2860
P921
P1476
A Phase 3, Multicenter, Open-L ...... lts With Binge Eating Disorder
@en
P2093
James Hudson
Jana Radewonuk
M Celeste Ferreira-Cornwell
Maria Gasior
Susan L McElroy
P2860
P304
P356
10.1097/JCP.0000000000000702
P407
P577
2017-04-05T00:00:00Z